Free Trial
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel
NYSEAMERICAN:ARMP

Armata Pharmaceuticals Q3 2026 Earnings Date & Estimates

Armata Pharmaceuticals logo
$3.22 +0.13 (+4.05%)
As of 12:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Armata Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Armata Pharmaceuticals in Q3 2026

Armata Pharmaceuticals is expected to post earnings of -$0.57 per share on revenue of $450 thousand. Armata Pharmaceuticals last reported on August 12, 2026, posting -$0.27 per share and beating the -$0.4450 consensus estimate. Armata Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.57
Expected Revenue
$450 thousand

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.27 (Beat by +$0.1750)
Last Quarter Revenue
$2.51 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Armata Pharmaceuticals Q3 2026 Earnings FAQ

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Armata Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Armata Pharmaceuticals to post earnings of -$0.57 per share for Q3 2026.

The consensus revenue estimate for Armata Pharmaceuticals is $450 thousand for Q3 2026.

Armata Pharmaceuticals Earnings Headlines

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
October 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-strengthens-intellectual-property-portfolio-with-two-recent-patent-issuances-in-the-united-states-302900574.html
JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)
September 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4834797/jonestrading-reaffirms-their-buy-rating-on-armata-pharmaceuticals-armp/
Financial Legend: “Big trouble ahead …”
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
November 4 at 1:00 AM  |  Weiss Ratings (Ad)
Armata Pharmaceuticals Receives Additional Non-Dilutive Funding To Support AP-SA02 Phase 3 Development
September 23, 2026  |  marketscreener.comM
Armata Gets $3.7M DoW Funding For AP-SA02 Phase 3 Development; Stock Down
September 23, 2026  |  rttnews.comhttps://www.rttnews.com/3693319/armata-gets-3-7m-dow-funding-for-ap-sa02-phase-3-development-stock-down.aspx
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
September 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-receives-3-7-million-in-additional-non-dilutive-funding-from-us-department-of-war-to-support-advancement-of-ap-sa02-phase-3-development-302886960.html
See More Armata Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email.

About Armata Pharmaceuticals

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Its programs have been directed toward conditions including chronic pulmonary infections in people with cystic fibrosis, as well as bloodstream and other difficult-to-treat bacterial infections. Armata also develops engineered phages and phage-based combination therapies intended to improve antibacterial activity and address resistance.

Armata is headquartered in Marina del Rey, California, and conducts research and clinical-development activities in the United States. The company was formerly known as AmpliPhi Biosciences and adopted the Armata Pharmaceuticals name in 2019. Its operations are led by President and Chief Executive Officer Todd R. Patrick.

View Armata Pharmaceuticals Profile
Earnings Tools